Voyager Therapeutics reported financial results for the second quarter of 2026, posting an earnings per share of negative forty cents, which outperformed analyst consensus expectations. Quarterly collaboration and license revenues came in at approximately 3.17 million dollars, reflecting ongoing partnership milestones and research funding agreements. Management continues to manage operating expenses carefully, allocating capital toward advancing its proprietary neurogenetic pipeline and expanding its advanced capsid discovery platform initiatives.